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ABSTRACT
Phenformin’s recently demonstrated efficacy in melanoma and Gleevec’s
demonstrated anti-proliferative action in chronic myeloid leukemia may lie within
these drugs’ significant pharmacokinetics, pharmacodynamics and structural
homologies, which are reviewed herein. Gleevec’s success in turning a fatal leukemia
into a manageable chronic disease has been trumpeted in medical, economic, political
and social circles because it is considered the first successful targeted therapy.
Investments have been immense in omics analyses and while in some cases they
greatly helped the management of patients, in others targeted therapies failed to
achieve clinically stable recurrence-free disease course or to substantially extend
survival. Nevertheless protein kinase controlling approaches have persisted despite
early warnings that the targeted genomics narrative is overblown. Experimental and
clinical observations with Phenformin suggest an alternative explanation for Gleevec’s
mode of action. Using 13C-guided precise flux measurements, a comparative multiple
cell line study demonstrated the drug’s downstream impact on submolecular fatty
acid processing metabolic events that occurred independent of Gleevec’s molecular
target. Clinical observations that hyperlipidemia and diabetes are both reversed in
mice and in patients taking Gleevec support the drugs’ primary metabolic targets
by biguanides and statins. This is evident by structural data demonstrating that
Gleevec shows pyridine- and phenyl-guanidine homology with Phenformin and
identical phenylcarbamoyl structural and ligand binding homology with Lipitor. The
misunderstood mechanism of action of Gleevec is emblematic of the pervasive flawed
reasoning that genomic analysis will lead to targeted, personalized diagnosis and
therapy. The alternative perspective for Gleevec’s mode of action may turn oncotargets
towards metabolic channel reaction architectures in leukemia and melanoma, as well
as in other cancers.
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INTRODUCTION

In their excellent paper Petrachi et al. [7] reiterate
the significant therapeutic potential of Phenformin as
a metabolic modulator of stem cell functions in therapy
resistant melanoma, which aims the same metabolic
oncotarget in leukemia and melanoma as an experimental
evidence for an alternative explanation for Gleevec’s
mode of action. Previous in vitro studies have thrown into
similar question whether the single-target kinase signal
blocking mechanism is indeed the primary mechanism
for STI-571’s mode of action [6] using 13C-guided
precise flux measurements, in a comparative multiple cell
line study. Targeted 13C-glucose tracer fate association
studies demonstrated the drugs’ downstream impact
on submolecular fatty acid processing and deuterium
depleting metabolic events that occurred independent of
Gleevec’s molecular target. Clinical observations that
hyperlipidemia and diabetes are both reversed in mice and
in patients taking Phenformin and Gleevec support the
drugs’ primary metabolic targets [5, 8-10].
The structural homology between Phenformin
and Gleevec certainly links Petrachi et al.’s work
in melanoma [7] to Gleevec’s clinical efficacy in
leukemia due to their shared metabolic effects rather
than the generally accepted mechanism of BCR-ABL
tyrosine kinase blockage. Gleevec’s chemical structure
(Chemical Abstract service (CAS) Registry Number:
152459-95-5) is that of an amino-phenyl guanidine

Gleevec’s (Gleevec; Imatinib-mesylate, Glivec,
STI-571) demonstrated anti-proliferative action in chronic
myeloid leukemia ushered in the era of targeted therapies
with claims that the drug blocks the constitutively
active BCR-ABL tyrosine kinase thereby inhibiting
phosphorylation of multiple downstream proteins of the
mitogenic signaling pathways [1]. Gleevec’s success
in turning a fatal leukemia into a manageable chronic
disease has been trumpeted in medical, economic,
political and social circles because it is considered the
first successful targeted therapy resulting from decadelong massive explorations of the genome [2]. Partly as a
result of Gleevec’s clinical success, genomic reductionism
has almost completely overtaken medical thinking,
dismantled model- and hypothesis driven research efforts,
monopolized funding, and diverted medical education
and therapy considerations towards personalized genomic
platforms described as big sequencing data biology [3].
Omics approaches continue to dominate costly drug
development efforts despite decades-long failures [4].
This collective enthusiasm for Gleevec and significant
investments in omics with excessive economic, public,
and political expectations, have persisted despite early
warnings that the targeted genomic narrative is overblown
[5, 6].

Figure 1: Structural homologies between Gleevec, Phenformin and Lipitor. Pharmacodynamically modified (cleaved)

Gleevec after binding (please see Figure 2 for binding homologies) has identical phenylcarbamoyl overlap with Lipitor (blue circles) that
are produced by first round drug modification pharmacodynamics reactions involving oxidation and cleavage by cytochrome P450 family
3 subfamily A member 4 enzymes. Green cylinders indicate similar phenyl-pyrrole (Lipitor) and phenyl-piperazine (Gleevec) derivatives
after the dihydroxyheptanoic acid residue is cleaved typically by β carbon oxidation. Orange circles show Phenformin and Gleevec sharing
phenethylcarbamimidoyl- and pyridine-methyl-guanidine groups. Lactic acidosis is a common side effect of diguanidine drugs, which is
also described in Gleevec [6] and Metformin [12, 31] treated cell cultures, as well as in Gleevec treated clinically drug resistant cells [22,
23].
www.impactjournals.com/oncotarget
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derivative with significant structural, pharmacokinetics
and pharmacodynamics homologies with Phenformin
and atorvastatin (Figure 1). Like these two latter drugs
Gleevec shows contextual inhibitory effect on thiolase,
as well as various competitive pentose-phosphate as well
as methyl-glutaryl- reductases involved in cholesterol
and new cellular membrane synthesis, hence exhibiting
an anti-proliferative action. Amino-phenyl class natural
compounds [11], the guanidine derivative metformin
[12] and Gleevec [6], which harbors both structural
components, readily inhibit HMG-CoA reductase activity
and thus divert acyl- and acetyl-residues towards complete
fatty acid oxidation (β carbon) in mitochondria. Thereby
contextual factors such as deuterium depleting ketogenic
substrate oxidation, i.e. the complete breakdown of fatty
acids in the expense of carbohydrates in mitochondria
to yield metabolic water [13, 14] determine Gleevec’s
efficacy, regardless of a cell’s BCR-ABL status. The
complete ketogenic catabolic mechanism of Gleevec

occurs in a drug-class specific manner, i.e. the same
effects are observed with virtually all guanides and statins
[15]. Striking pharmacodynamics similarities include that
Gleevec undergoes first passage activation by gut/liver
CYP3A4 (cytochrome P450 3A4; EC 1.14.13.97) to yield
biologically active N-demethylated piperazine derivatives,
Gleevec is highly (98%) bioavailable after a single oral
dose, rapidly cleaved by oxidation to yield a guanide
while structurally modified [16] so that only about 25%
of the drug can be recovered from circulation unchanged
after several passages. Gleevec also bears elimination in
the bile and feces like biguanides and statins. Figure 1
shows pyridine- and phenyl-guanidine homology between
Gleevec and Phenformin (Figure 1, orange circles) and
identical phenylcarbamoyl structural homology of Gleevec
with Lipitor (Figure 1, blue circles).
It is worth knowing that all analogues designed
to treat Gleevec resistance share guanide structural
similarities and target the same ATP pocket for binding,

Figure 2: Gleevec’s proton sharing binding properties via overlapping structural amino acid sites in BCR-ABL and
Lipitor and Phenformin binding ligands. Drug binding low affinity and high capacity hydrogen bonding architectures are shared

among Lipitor, Phenformin, Metformin and Gleevec. Lipitor has similar proton bridging architectures by its structural homologies with
Gleevec (red arrows). These include histidine, leucine, iso-leucine, as well as serine, as visualized by two dimensional protein−ligand
complex architectures [19]. Gleevec’s guanidine group binds to BCR-ABL through Threonine-315 (green arrows), which is similar to
the binding of Metformin and Phenformin to the AMPK-γ subunit to induce conformational changes and promote the phosphorylation of
Threonine-172 in AMPK. Stoichiometric modifications of Threonine-315 and Methionine-319 in BCR-ABL by the phenethylcarbamimidoyland pyridine-methyl-guanidine groups of Gleevec are evident. (Black dashed lines in Lipitor indicate hydrogen bonds, salt bridges, and
metal interactions. The green solid line (not the arrows) shows hydrophobic interactions and green dashed lines show π-π and π-cation
interactions, which are determined by geometric criteria as described in [19].
www.impactjournals.com/oncotarget
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all of which result in remissions in chronic myeloid
leukemia. Petrachi et al.’s work [7] may extend arguments
that phenyl-guanidine homologies between Gleevec
and Phenformin work through similar metabolic and
ligand binding architectures targeting kinase domains
via six hydrogen bond interactions [17]. Such hydrogen
bonds involve the pyridine-N and backbone-NH of Met318 and the hydroxyl aminopyrimidine side chain of
Thr-315 [18]. Figure 2 summarizes Gleevec’s proton
sharing binding properties via distinct amino acid
residues that are also known to bind Lipitor, Metformin
and Phenformin in their own protein targets. These low
affinity and high capacity drug binding architectures are
evidently shared by Lipitor, Phenformin and Gleevec,
which include histidine, leucine, iso-leucine, as well as
serine, as specific amino acid ligands in two dimensional
visual structures [19]. Gleevec’s guanidine group binds
to BCR-ABL through Threonine-315 (green arrow),
which is similar to the binding mechanism of Metformin
and Phenformin to the AMPK-γ subunit to induce
conformational changes during the phosphorylation of
Threonine-172 of AMPK. Stoichiometric modifications
of Threonine-315 and Methionine-319 in BCR-ABL
by the phenethylcarbamimidoyl- and pyridine-methylguanidine groups of Gleevec (Figure 2) induce metabolic
rearrangements according to the deuterium depleting
ketogenic substrate utilization metabolic phenotype, as
described in 13C-glucose guided metabolomics studies [6,
12]. The tripartite mechanism using 1) Lipitor-like binding
architectures to BCR-ABL with 2) a serine/threonine
kinase targeting guanidine mechanism provides 3)
anticancer and antidiabetic properties [20] to Metformin,
Phenformin and Gleevec. Metabolic adaptation of BCRABL-negative Gleevec sensitive rat glioblastoma (C6)
cells can be primed by hydroxycarbamide (hydroxyurea,
HU) treatment for a more robust metabolic response [21],
a structure also embedded in Gleevec by conditional
oxidation of its guanide group (Figure 1, red circles).
This underlines the significance of the primary metabolic
mechanism of Gleevec’s action in a broad range of
cellular phenotypes by the alternate fueling of the TCA
cycle according to a metabolic branching for acetylCoA in ketosis [21-24]. These studies demonstrate
Gleevec’s impact on fatty acid metabolic events that
occurs independent of its molecular target. On the other
hand Gleevec resistance is maintained in glycolytic cells
with intact BCR-ABL by elevated glucose uptake and
lactate production with small new fatty acid fractions and
limited turnover. As a result, elevated glucose uptake with
nonoxidative pentose processing and intense glycolysis,
while lacking significant fatty acid turnover, are used as
sensitive metabolic markers for early detection of Gleevec
resistance in both BCR-ABL-positive and BCR-ABLnegative cells [22, 23]. More specifically, therapeutic
concentrations of Gleevec (0.1-1.0 micromol/L) decreased
glucose uptake while increasing the activity of the
www.impactjournals.com/oncotarget

mitochondrial Krebs cycle with improved mitochondrial
acetyl-CoA catalysis. Unlike standard chemotherapeutics,
Gleevec, without cytocidal activity, reversed the Warburg
effect by switching cells from glycolysis to mitochondrial
acetyl-CoA breakdown while limiting glucose uptake and
improving energy homeostasis [24].
In summary, the excellent paper by Petrachi et al. [7]
that demonstrates the therapeutic potential of the biguanide
class metabolic regulator Phenformin in melanoma
lies close to pharmacokinetics, pharmacodynamics,
structural and ligand binding homologies between
Phenformin, Lipitor and Gleevec. These drugs therefore
aim the same mitochondrial metabolic oncotarget as in
leukemia. This work also points to the misunderstood
mechanism of action of Gleevec, which is emblematic
of the pervasive flawed reasoning that genomic analysis
will lead to targeted, personalized diagnosis and therapy.
It is evident that oncotargets are moving to the more
reliable and phenotypically conserved metabolic arena.
A conscious evaluation of the genomics era offered
herein and sequencing efforts point again to inherently
constructed failure paths in big biology [25] as well as
severe conceptual shortcomings of personalized oncology
and medicine [26-29]. The study of Petrachi et al. [7]
opens directions from the narrow focus on genetic
signaling mechanisms towards metabolically driven
submolecular targets, in particular ketogenic metabolism’s
deuterium depletion in cytoplasmic and mitochondrial
matrix water [13, 14], based on the clear structural and
functional overlaps among targeted kinase inhibitors and
metabolically positioned drugs for translational research
and clinical medicine [30].

CONFLICTS OF INTERESTS
Gábor Somlyai is employed by HYD, LLC. T.
Que Collins is employed by and László G. Boros has
academic consulting arrangements with 13Cignature
2
Health Metabolic Clinic, Santa Monica, CA 90403,
USA. Dr. Boros is an academic advisor of SiDMAP, LLC
under FDA/OO/OFBA/OAGS/DAP branch work order
HHSF223201610399A. None of the above entities are
traded publically or share views necessarily with that of
the authors.

FUNDING
The work was supported by the Hirshberg
Foundation for Pancreatic Cancer Research, the UCLA
Clinical Translational Science Institute (UL1TR000124)
and the UCLA Center for Excellence in Pancreatic
Diseases - Metabolomics Core (1-P01 AT003960-01A1)
to LGB. The Gleevec mechanism of metabolic action
project described was supported by the National Center
for Advancing Translational Sciences through UCLA
CTSI Grant UL1TR001881-01. Targeted 13C tracer drug
50190

Oncotarget

efficacy marker data diagnostics for cancer were partially
supported by the European Regional Development Fund,
Central Hungary Operative Program, New Széchenyi Plan
(KMOP-1.1.4-11/A-2011-01-05) to GS. Stable isotope
profiles in health and disease using metabolic ketosis were
funded by the EPIGENIX foundation under LABIOMED
project # 31071-01 to LGB. The content is solely the
responsibility of the authors and does not necessarily
represent the official views of the NIH or that of the FDA.
The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the
manuscript.

synthase inhibitor C75. Metabolomics. 2012; 8:201-210.
12. Cantoria MJ, Boros LG, Meuillet EJ. Contextual inhibition
of fatty acid synthesis by metformin involves glucosederived acetyl-CoA and cholesterol in pancreatic tumor
cells. Metabolomics. 2014; 10:91-104.
13. Boros LG, Somlyai G. Compartmentalized NADPH
Synthesis, Intramolecular Deuterium Disequilibrium and
Water Pools of Mammalian Cells. Comment on: Lewis CA,
et al., Tracing compartmentalized NADPH metabolism in
the cytosol and mitochondria of mammalian cells. Mol Cell.
2014; 55:253-263.
14. Boros LG, D’Agostino DP, Katz HE, Roth JP, Meuillet EJ,
Somlyai G. Submolecular regulation of cell transformation
by deuterium depleting water exchange reactions in the
tricarboxylic acid substrate cycle. Med Hypotheses. 2016;
87:69-74. doi: 10.1016/j.mehy.2015.11.016.

REFERENCES
1.

Savage DG, Antman KH. Imatinib mesylate-a new oral
targeted therapy. N Engl J Med. 2002; 346:683-693.

2.

Collins F, Galas D. A new five-year plan for the U.S.
Human Genome Project. Science. 1993; 262:43-46.

3.

Green ED, Watson JD, Collins FS. Human Genome Project:
Twenty-five years of big biology. Nature. 2015; 526:29-31.
doi: 10.1038/526029a.

4.

Morgan G, Aftimos P, Awada A. Current-day precision
oncology: from cancer prevention, screening, drug
development, and treatment - have we fallen short of the
promise? Curr Opin Oncol. 2016; 28:441-446.

5.

Boros LG, Lee WN, Cascante M. Imatinib and chronicphase leukemias. N Engl J Med. 2002; 347:67-68.

6.

Boren J, Cascante M, Marin S, Comín-Anduix B, Centelles
JJ, Lim S, Bassilian S, Ahmed S, Lee WN, Boros LG.
Gleevec (STI571) influences metabolic enzyme activities
and glucose carbon flow toward nucleic acid and fatty
acid synthesis in myeloid tumor cells. J Biol Chem. 2001;
276:37747-37753.

7.

8.

9.

15. Glodkowska-Mrowka E, Mrowka P, Basak GW,
Niesiobedzka-Krezel J, Seferynska I, Wlodarski PK,
Jakobisiak M, Stoklosa T. Statins inhibit ABCB1 and
ABCG2 drug transporter activity in chronic myeloid
leukemia cells and potentiate antileukemic effects of
imatinib. Exp Hematol. 2014; 4:439-447. doi: 10.1016/j.
exphem.2014.02.006.
16. Gschwind HP, Pfaar U, Waldmeier F, Zollinger M, Sayer
C, Zbinden P, Hayes M, Pokorny R, Seiberling M, BenAm M, Peng B, Gross G. Metabolism and disposition of
imatinib mesylate in healthy volunteers. Drug Metabolism
and Disposition. 2005; 33:1503-1512.
17. Druker BJ, Lydon NB. Lessons learned from the
development of an abl tyrosine kinase inhibitor for chronic
myelogenous leukemia. J Clin Invest. 2000; 105:3-7.
18. Eck MJ1, Manley PW. The interplay of structural
information and functional studies in kinase drug design:
insights from BCR-Abl. Curr Opin Cell Biol. 2009; 21:288295. soi: 10.1016/j.ceb.2009.01.014.

Petrachi T, Romagnani A, Albini A, Longo C, Argenziano
G, Grisendi G, Dominici M, Ciarrocchi A, Dallaglio
K. Therapeutic potential of the metabolic modulator
phenformin in targeting the stem cell compartment in
melanoma. Oncotarget. 2017; 8:6914-6928. doi: 10.18632/
oncotarget.14321.

19. Stierand K, Rarey M. Drawing the PDB: Protein−Ligand
Complexes in Two Dimensions. ACS Med Chem Lett.
2010; 1:540-545. doi: 10.1021/ml100164p.
20. Hardie GD. AMPK: A Target for Drugs and Natural
Products with Effects on Both Diabetes and Cancer.
Diabetes. 2013; 62:2164-2172.

Choi SS, Kim ES, Jung JE, Marciano DP, Jo A, Koo JY,
Choi SY, Yang YR, Jang HJ, Kim EK, Park J, Kwon HM,
Lee IH, et al. PPAR antagonist Gleevec improves insulin
sensitivity and promotes the browning of white adipose
tissue. Diabetes. 2016; 65:829-839.

21. Serkova N, Boros LG. Detection of resistance to imatinib
by metabolic profiling: clinical and drug development
implications. Am J Pharmacogenomics. 2005; 5:293-302.
doi: 10.2165/00129785-200505050-00002.

Fountas A, Diamantopoulos LN, Tsatsoulis A. Tyrosine
Kinase Inhibitors and Diabetes: A Novel Treatment
Paradigm? Trend Endocrin Metab. 2015; 26:643-656.

10. Gottardi M, Manzato E, Gherlinzoni F. Imatinib and
hyperlipidemia. N Engl J Med. 2005; 353:2722-2723.

22. Kominsky DJ, Klawitter J, Brown JL, Boros LG, Melo JV,
Eckhardt SG, Serkova NJ. Abnormalities in glucose uptake
and metabolism in imatinib-resistant human BCR-ABLpositive cells. Clin Cancer Res. 2009; 15:3442-3450. doi:
10.1158/1078-0432.CCR-08-3291.

11. Harris DM, Li L, Chen M, Lagunero FT, Go VL, Boros
LG. Diverse mechanisms of growth inhibition by
luteolin, resveratrol, and quercetin in MIA PaCa-2 cells:
a comparative glucose tracer study with the fatty acid

23. Klawitter J, Kominsky DJ, Brown JL, Klawitter J,
Christians U, Leibfritz D, Melo JV, Eckhardt SG, Serkova
NJ. Metabolic characteristics of imatinib resistance in
chronic myeloid leukaemia cells. Br J Pharmacol. 2009;

www.impactjournals.com/oncotarget

50191

Oncotarget

158:588-600. doi: 10.1111/j.1476-5381.2009.00345.x

28. Joyner MJ, Paneth N. Seven Questions for Personalized
Medicine. JAMA. 2015; 314:999-1000. doi: 10.1001/
jama.2015.7725.

24. Gottschalk S, Anderson N, Hainz C, Eckhardt SG, Serkova
NJ. Imatinib (STI571)-mediated changes in glucose
metabolism in human leukemia BCR-ABL-positive cells.
Clin Cancer Res. 2004; 10:6661-6668.

29. Prasad V. The precision-oncology illusion. Nature. 2016
537:S63. Doi:: 10.1038/537S63a.

25. Fukushima M. Constructing failure in big biology: The
socio-technical anatomy of Japan’s Protein 3000 Project.
Soc Stud Sci. 2016; 46:7-33.

30. Boros LG, Collins TQ, Somlyai G. What to eat or what not
to eat - that is still the question. Neuro-Oncology. 2017; (in
print) doi: 10.1093/neuonc/now284.

26. Boros LG. Metabolic targeted therapy of cancer: current
tracer technologies and future drug design strategies in the
old metabolic network. Metabolomics. 2005; 1:11-15.

31. Cantoria MJ, Patel H, Boros LG, Meuillet EJ. Metformin
and Pancreatic Cancer Metabolism, Pancreatic Cancer Insights into Molecular Mechanisms and Novel Approaches
to Early Detection and Treatment. Kelly McCall (Ed.),
2014; InTech, doi: 10.5772/57432.

27. Joyner MJ, Paneth N, Ioannidis JP. What happens
when underperforming big ideas in research become
entrenched? JAMA. 2016; 316:1355-1356. doi: 10.1001/
jama.2016.11076.

www.impactjournals.com/oncotarget

50192

Oncotarget

